|
Search
Collections
Benchmarks
Upload document
Organization
resistanceBio
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 abstract
Abstract
Differentiating ensartinib from lorlatinib and alectinib for first line use in an ALK+ non-small cell lung cancer preclinical model (ResCu).
Org:
resistanceBio,
San Carlos, CA,
